Phase I trial of sulindac plus 5-fluorouracil and levamisole: Potential adjuvant therapy for colon carcinoma

Clinical Cancer Research

Volumn 2, Issue 1, 1996, Pages 37-41

  Sinicrope, Frank A ^a,b   Pazdur, Richard ^a   Levin, Bernard ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; LEVAMISOLE; SULINDAC;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEVAMISOLE; MALE; MIDDLE AGED; SULINDAC;

EID: 0030070735     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Moertel, C. G , Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., Veeder, M. H., and Maillard, J. A. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med., 322: 352-358, 1990.
2. Thun, M. J., Namboodiri, M. M., and Heath, C. W., Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1991.
3. Rosenberg, L., Palmer, J. R., Zauber, A. G., Warshauer, M. E., Stolley, P. D., and Shapiro, S. A. A hypothesis: nonsteroidal antiinflammatory drugs reduce the incidence of large bowel cancer. J. Natl. Cancer Inst., 83: 355-358, 1991.
4. Kune, G. A., Kune, S., and Watson, L. F. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer (Phila.). 48: 4399-4404, 1988.
5. Peleg, G., Melbach, H. T., Brown, S. H., and Wilcox, C. M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Intern. Med., 154: 394-399, 1994.
6. Schreinemachers, D. M., and Everson, R. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 5: 138-146, 1994.
7. Giovannucci, E., Rimm, E. R., Stampfer, M. J., Colditz, G A., Ascherio, A., and Willen, W. C. Aspirin use and the risk of Colorectal cancer and adenoma in male health professionals. Ann Intern. Med., 121: 241-246, 1994.
8. Waddell, W. R., Ganser. G. F., Cerise. E. J., and Loughry, R. W. Sulindac for polyposis of the colon. Am. J. Surg., 157: 175-179, 1989.
9. Waddell, W. R., and Loughry, R. W. Sulindac for polyposis of the colon. J. Surg. Oncol. 24: 83-87, 1983.
10. Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M., and Attali, P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101: 635-639, 1992.
11. Rigau, J., Piquè, J. M., Rubio, E., Planas, R., Tarrech, J. M., and Bordas, J. M. Effects of long-term sulindac therapy on colonie polyposis. Ann. Intern. Med., 115: 952-954, 1991.
12. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. A. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 18: 1313-1316, 1993
13. Moorghen, M., Ince, P , Finney, R. J., Sunter, J. P., Appleton, D. R., and Watson, A. J. A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J. Pathol., 156: 341-347, 1988.
14. Pollard, M., and Luchert, P H. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J. Natl. Cancer Last., 70: 1103-95, 1983.
15. Nansawa, T., Sato, M., Tam, M., Kudo, T., Takahashi, T., and Goto, A. Inhibition of development of methylnitrosurea-induced rat colon tumors by indomethacin treatment. Cancer Res , 41: 1954-1957, 1981.
16. Reddy, B. S., Maruyama, H., and Kelloff, G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res., 47: 5340-5346, 1987.
17. Kudo, T., Narisawa, T., and Abo, S. Antitumor activity of indomethacin or methylazoxymethanol-induced large bowel tumors in rats. Gann, 71: 260-264, 1980.
18. Skinner, S. A., Penney, A. G., and O'Brien, P. E. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch. Surg., 126: 1094-1096, 1991.
19. Rao, C. V., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V., and Reddy, B. S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55: 1464-1472, 1995.
20. Lundholm, K., Gellin, J., Hyltander, A., Lonnroth, C., Sandstrom, R., Svaninger, G., Korner, M., Gulich, M., Karrefors, I., Norli, B., Hafstrom, L. O., Kewenter, J., Olbe, L., and Lundell, L. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res., 54: 5602-5606, 1994.
21. Ross, D. S., Bitzer, D., Roy, T., and Murphey, J. E. Piroxicam inhibits the growth of an adenocarcinoma isograft in Fisher rats. J. Surg. Res., 45: 249-253, 1988.
22. Tanaka, Y., Tanaka, T., and Ishitsuka, H. Antitumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants. Cancer Res., 49: 5935-5939, 1989.
23. Gelin, J., Andersson, C., and Lundholm, K. Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res., 51: 880-885, 1991.
24. Fulton, A. M. Interaction of natural effector cells and prostaglandins in the control of metastasis. J. Natl Cancer Inst., 78: 735-741, 1987.
25. Fulton, A. M. Inhibition of experimental metastasis with indomethacin. Role of macrophages and natural killer cells. Prostaglandins, 35: 413-425, 1988.
26. Bennett, A , Berstock, D. A., and Carrol, M. A Increased survival of cancer-bearing mice treated with inhibitors of prostaglandin synthesis alone or with chemotherapy. Br. J. Cancer. 45: 762-768, 1982.
27. Marnett, L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52: 5575-5589, 1992.
28. 2-mediated suppression of cellular immunity in colon cancer patients. Surgery, 95: 71-77, 1984
29. Braun, D. P., Bonomi, P. D., Taylor, S. G., and Harris, J. E. Modification of the effects of cytotoxic chemotherapy on the immune responses of cancer patients with a nonsteroidal anti-inflammatory drug, piroxicam. A pilot study of the Eastern Cooperative Oncology Group. J. Biol. Response Modif., 6: 331-345, 1987.
30. Wiltrout, R. H., Herberman, R. B., Zhang, S-R., Chirigos, M. A., Ortaldo, J. R., Green, K. M., Jr., and Talmadge, J. E. Role of organassociated NK cells in decreased formation of experimental metastases in lung and liver. J. Immunol., 134: 4267-4275, 1985.
31. Timer, J., Chen, Y. Q., Liu, B., Bazar, R., Taylor, J. D., and Honn, R. V. The lipoxygenase metabolite 12(5)-HETE promotes αIIβ3 integrin-mediated tumor-cell spreading on fibronectin. Int. J. Cancer, 52: 594-603, 1992.
32. 1 and copper in angiogenesis. J. Natl. Cancer Inst., 69: 475-482, 1982.
33. Carson, J. L., Strom, B. L., Soper, K. A., West, S. L., and Morse, M. L. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch. Intern. Med., 147: 85-88, 1987.
34. Griffin, M. R., Piper, J. M., Daugherty, J. R., Snowden, M., and Ray, W. A. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann. Intern. Med., 114: 257-263, 1991.
35. Duggan, J. M., Dobson, A. J., Johnson, H., and Fahey, P. Peptic ulcer and nonsteroidal anti-inflammatory agents. Gut, 27: 929-933, 1986.
36. Soll, A. H., Weinstein, W. M., Kurata, J., and McCarthy, D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann. Intern. Med., 114: 307-319, 1991.
37. Chu, E., and Takimoto, C. H. Antimetabolites. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 362-365. Philadelphia: J. B. Lippincott Co., 1993.
38. Lanza, F. L., Nelson, R. S., and Rack, M. F. A controlled endoscopie study comparing the toxic effects of sulindac, naproxen, aspirin, and placebo on the gastric mucosa of healthy volunteers. J. Clin. Pharmacol., 24: 89-95, 1984.
39. Caruso, I., and Bianchi Porro, G. Gastroscopic evaluation of antiinflammatory agents. Br. Med J., 280: 75-78, 1980.
40. Agrawal, N. M., Roth, S., Graham, D. Y., White, R. H., Germain, B., Brown, J. A., and Stromatt, S. C. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann. Intern. Med., 115: 195-200, 1991.
41. Ehsanullah, R. S., Page, M. C., Tildesley, G., and Wood, J. R. Prevention of gastroduodenal damage induced by non-steroidal antiinflammatory drugs: controlled trial of ranitidine. Br. Med. J., 297; 1017-21, 1988.
42. Robinson, M. G., Griffin, J. W., Jr., Bowers, J., Kogan, F. J., Kogut, D. G., Lanza, F. L., and Warner, C. W. Effect of ranitidme on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig. Dis. Sci., 34: 424-8, 1989.
43. Graham, D. Y., Agrawal, N. M., and Roth, S. H. Prevention of NSAID-induced gastric ulcer with misoprostol: multicenter, double-blind, placebo-controlled trial. Lancet, 2: 1277-1280, 1988.
44. Graham, D. Y., White, R. H., Moreland, L. W., Schubert, T. T., Katz, R., Jaszewshi, R., Tindall, E., Triadafilopoulos, G., Stromatt, S. C., Teoh, L. S., and the Misoprostol Study Group: Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann. Intern. Med., 119: 257-262, 1993.
45. Walan, A., Bader, J. P., Classen, M., Lamers, C. B., Piper, D. W., Rutgersson K., and Eriksson, S. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N. Engl. J. Med., 320: 69-75, 1989.
46. Miller, J. L. Marrow aplasia and sulindac. Ann. Intern. Med., 92: 129, 1980.
47. Sanz, M. A., Martinez, J., Gomis, F., and Garcia-Borras, J. J. Sulindac-induced bone marrow toxicity. Lancet, 2: 802, 1980.
48. Andrews, R., and Russel, N. Aplastic anemia associated with nonsteroidal anti-inflammatory drug: relapse after exposure to another such drug. Br. Med. J., 301: 38, 1990.
49. Piazza, G. A., Kulchak Rahm, K. L., Krutzsch, M., Sperl, G., Shipp Paranka, N., Gross, P. H., Brendel, K., Burt, R. W , Alberts, D. S., Pamukcu, R., and Ahnen, D. J. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55: 3110-3116, 1995.
50. Stewart, B. W. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J. Natl. Cancer Inst., 86: 1286-1296, 1994.
51. Sinicrope, F. A., Ruan, S., Clearly, K. R., Lee, J. J., and Levin, B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res., 55: 237-241, 1995.